menu

Evidence and Value of Prescription Omega-3 Fatty Acids in Cardiovascular Disease Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Evidence and Value of Prescription Omega-3 Fatty Acids in Cardiovascular Disease Management

close
0.25 credits
15 Minutes
Evidence and Value of Prescription Omega-3 Fatty Acids in Cardiovascular Disease Management
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Despite the success of statin therapy in significantly reducing patients’ LDL-cholesterol and the risk of cardiovascular events, there remains a considerable need for event reduction. Fortunately, we now have findings from the REDUCE-IT landmark trial on icosapent ethyl that could help us find a way to meet that need.

    This activity will provide practical information on the evidence, clinical utility, and use of icosapent ethyl in patients at risk of ASCVD events.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Host:
    Deepak L. Bhatt, MD
    FINANCIAL DISCLOSURE:
    Contracted Research: Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    Faculty:
    Mary Katherine Cheeley, MD
    FINANCIAL DISCLOSURE:
    Consulting Fees: Glaxo Smith Kline
    Other: Investigator Initiated Study Grant- Sanofi/Regeneron Alliance

    Daniel E. Hilleman, MD
    FINANCIAL DISCLOSURE:
    Consulting Fees:  Heron Therapeutics
    Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Amarin

    Reviewers/Content Planners/Authors:
    Ben Caref, PhD has nothing to disclose

    The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and cost utility of ASCVD therapy in practice
  • Target Audience

    This on-line CME activity is targeted for Pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    CONTINUING PHARMACY EDUCATION
    Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education. 

    (Universal Activity Number -  JA4008162-9999-20-2048-H01-P )

    Type of Activity : Knowledge

    Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)

    Jointly provided by Postgraduate Institute for Medicine and Medtelligence. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Despite the success of statin therapy in significantly reducing patients’ LDL-cholesterol and the risk of cardiovascular events, there remains a considerable need for event reduction. Fortunately, we now have findings from the REDUCE-IT landmark trial on icosapent ethyl that could help us find a way to meet that need.

    This activity will provide practical information on the evidence, clinical utility, and use of icosapent ethyl in patients at risk of ASCVD events.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Host:
    Deepak L. Bhatt, MD
    FINANCIAL DISCLOSURE:
    Contracted Research: Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    Faculty:
    Mary Katherine Cheeley, MD
    FINANCIAL DISCLOSURE:
    Consulting Fees: Glaxo Smith Kline
    Other: Investigator Initiated Study Grant- Sanofi/Regeneron Alliance

    Daniel E. Hilleman, MD
    FINANCIAL DISCLOSURE:
    Consulting Fees:  Heron Therapeutics
    Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Amarin

    Reviewers/Content Planners/Authors:
    Ben Caref, PhD has nothing to disclose

    The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and cost utility of ASCVD therapy in practice
  • Target Audience

    This on-line CME activity is targeted for Pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    CONTINUING PHARMACY EDUCATION
    Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education. 

    (Universal Activity Number -  JA4008162-9999-20-2048-H01-P )

    Type of Activity : Knowledge

    Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)

    Jointly provided by Postgraduate Institute for Medicine and Medtelligence. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/22/20